Many patients with unresectable hepatocellular carcinoma present with poor-prognosis features that have historically limited their representation in clinical trials. This expert perspective explores the evidence gap in these higher-risk populations, the role of emerging prospective data in systemic therapy, and why multidisciplinary care remains central to treatment decision‑making.
